The Financial Superstorm Coming for the Pharma Industry

Michael N. Abrams, MA, Rita E. Numerof, Ph.D., and Michael L. Ryan, Pharm.D.

Also available on the NAI website

The business of developing new medicines and bringing them to market has never been more challenging – and there’s no relief in sight. Indeed, the industry is facing what amounts to a financial superstorm over the next 4-5 years. Between evolving policies in play and growing financial pressures, the possibility of significant changes in the business is very real.

Between 2025 and 2030, the pharmaceutical industry is facing a “patent cliff” – loss of exclusivity (LOE) for many of its leading products. That spells the evaporation of between $236 and $400 billion in annual branded drug revenue as generic competition drives prices down.

In addition, there’s the Inflation Reduction Act (IRA). The first round of prices negotiated under the act became effective January 1, 2026. The ten medicines included were singled out for negotiation because they were so widely prescribed that they became targets for federal healthcare cost cutters. These drugs might have had 2-4 more years of exclusivity, but the IRA cut their peak earning cycle short. The process repeats annually, including more drugs each year.

At the same time, the Trump administration has extracted commitments from 26 of large and midsized pharma companies to reduce their prices on at least some of their medicines to the much lower prices charged in the EU. Further commitments made in lieu of paying tariffs include reshoring manufacturing plants to the tune of billions of dollars, committing to DTC sales via Trump Rx, contributing free active drug ingredients to the Strategic Active Pharmaceutical Reserve, and/or agreeing to launch future drugs in the U.S. at pricing similar to ex-U.S. pricing. While the impact of these commitments have been limited to date, the precedent being set has major future financial implications for the industry.

Throw in the looming implementation of MFN pricing rules, significant cost inflation, and capital constraints, and it’s no surprise that the financial dashboards of major pharmaceutical companies have been flashing red for some time.

Pharma companies recognize the need for action to ensure that the margins are there to keep investors from taking their capital elsewhere. Part of that will be finding new ways of working that will make the process of developing and commercializing new medicines faster and more effective. We have written about these ideas elsewhere.

But there is also the need to cut the cost of doing business. Contingent on various policy changes in process, we’ve come up with several actions pharma companies can take that would dramatically reduce their cost of operations and improve effectiveness.

One of these has to do with a very prominent political issue – pharmaceutical advertising. This has become a hot button for reform advocates who see the estimated $7 billion spent annually on TV advertising as inappropriate, dishonest, or worse. Indeed, these criticisms have found receptivity in the current Administration, which issued a presidential directive in September 2025 to HHS and FDA to eliminate the “adequate provision” loophole in rules governing advertising of medical products. This rule allows manufacturers to briefly summarize a drug’s major side effects during a 30-second commercial and point the consumer to a website, print ad, or toll-free number for the rest. If the rule were eliminated and all potential side effects needed to be fully explained in the commercial itself, it would make traditional television commercials impossible to fit into standard 30-to-60-second time slots, effectively ending the practice. At this time, the directive to eliminate the 1997 “adequate provision” loophole is actively moving through formal federal rulemaking.

The issue of pharma advertising has been controversial for years. Proponents have argued that ads have increased patient awareness and prompted patients to seek medical help who might have otherwise suffered in silence. On the other hand, there is little controversy over the suggestion that such advertising has damaged the reputation of the industry, giving the lie to industry claims that “it’s all about the science”. In Gallup’s 2025 industry ratings, Pharmaceuticals remained one of the three least favorably viewed sectors among 25 evaluated.1 Roughly six in ten Americans viewed the industry negatively. While advertising is not the sole source of the industry’s reputational problems, it serves to reinforce consumers’ concerns about high prices, perceived profiteering, and affordability – the very perceptions the industry would like to change. It’s worth asking whether the damage to the industry’s reputation is worth the incremental revenue. It’s also worth considering what the current course of the science means for mass advertising. As science continues to create solutions for increasingly specialized population segments, mass advertising becomes less effective.

If the Trump administration is successful in forcing a return to earlier standards of risk disclosure in product advertising, it would present an opportunity for pharma companies to lower costs, build their corporate brand, and repair their badly tarnished reputations. That opportunity would involve a shift from product-specific advertising to non-commercial therapeutic area marketing. The focus would be on dissemination of educational, clinical, and scientific information by pharmaceutical or biotech companies that focus entirely on a disease state or medical specialty rather than brand-level selling. The primary goal would be to address unmet medical needs, advance disease awareness, and facilitate scientific exchange without promoting a specific commercial product. In the process, companies could use the opportunity to build company credibility in specific therapeutic areas and make the case for economic and societal value provided by the industry – something that has been sorely neglected by industry supporters and critics alike. And from a financial perspective, it seems likely that such efforts would be far less costly than current product-promotion efforts.

The conventional wisdom in the industry is that TV advertising generates positive short-term ROI. If it didn’t, proponents argue, companies would have stopped these investments long ago. One of the challenges is that ROI is often inflated due to double counting and the need for greater precision in analyzing which parts of the marketing mix are generating the desired results. Oftentimes the analysis is done by advertising agencies who have a vested interest in the outcome, a point we’ll explore in more depth in a subsequent article.

The second strategic action that pharma manufacturers can take to lower costs is to finish the task of right-sizing the sales force. This too has been a focus of much discussion over the last decade, with only modest changes resulting. During the pandemic, when physician offices and hospital campuses were closed to reps, it became clear that the incremental sales of pharmaceutical products generated by sales force efforts is not sufficient to justify the cost of that activity. The truth is that decisions regarding which drugs will be on the formulary are increasingly being made by cross functional corporate groups in which physicians play a shrinking role relative to other, strategic considerations. Low end estimates of the cost of direct prescriber detailing range from 13.5B to 34.3B dollars.2,3 While physicians continue to want information on products, pharmaceutical companies can more than make up for what sales reps were doing by staffing up the ranks of medical liaisons and building out an AI-based informational program that is customized to the needs of key recipients.

Particularly in the case of specialty medications which are growing increasingly complex, physicians need to understand which one to use with different patients. Only a medical liaison can do that, not sales reps. And market access staff are the ones who need to be talking with economic buyers – the ones sitting around the executive and boardroom tables. Reluctance to change the model despite data that says it’s not working as it used to, reflects adherence to outmoded assumptions about the value of reps and the structure of healthcare delivery. Perhaps more importantly, it reflects the fact that many commercial leaders don’t have a clear picture of what to do instead and are afraid that competitors will fill their “slot” if they pull back reps. We’ll explore the underlying dynamics of this in another article in the series.

There’s another important opportunity for pharma companies fortunate enough to have products with mass market appeal selling at premium prices – cut your price. As we have seen with GLP-1 drugs, price rationalization shifted GLP-1s from a luxury, high-margin niche into a mass-market volume game. While per-unit net prices plunged to $245–$350, unprecedented payer coverage has unlocked a $200 billion global market. Ultimately, manufacturers using this strategy are sacrificing per-bottle margins but winning on massive volume and cheaper oral pill production, keeping the industry highly profitable. A future candidate for this strategy would be treatments for non-alcoholic steatohepatitis (NASH/MASH). Because these medicines are oral small-molecule pills rather than complex biologic injections, they are cheap to produce at scale. A low-margin, high-volume strategy like that used with GLP-1s could mirror that same success.

Despite the ongoing back and forth in Congress, pressure is growing for comprehensive healthcare reform that rewrites payment rules for medicines and services based on the value provided. Pharma companies need to take the long view that this reform is coming, and plan now, more than ever, to document the value of their medicines. At the same time, the pharma community needs to establish its credentials as an advocate for constructive change, not just in its own business, but across healthcare more generally. The reality is that old habits die hard. Continuing to put resources into a strategy that is increasingly ineffective and promises only to become more so doesn’t make sense when resources are likely to become more constrained. In the next article in the series, we cover some of the key sources of resistance and offer alternative solutions.